City Therapeutics Profit Margin

City Therapeutics posts a profit margin of 27.66% as of June 2020. That compares with 21.77% in the prior-year period — up 27.0% year over year. That is above the Healthcare sector average of 10.58%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, City Therapeutics's profit margin was 21.77%. The latest reading is 27.66% — a 27.0% year-over-year increase (period ending June 2020). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 10.58% is typical. City Therapeutics's 27.66% is higher that level. That is roughly 161.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

City Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 27.66% as of June 2020; use YoY and peer views to separate noise from signal.

Context for CTY's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 10.58%), and (3) consistency with growth and profitability. This page covers the first two; City Therapeutics's other metric pages and overview cover the third.